Recent Updates
Recently added Catalysts

IBIO-610

Phase 1

Obesity & Overweight | Small molecule | Metabolic |iBio, Inc.|Trials Updated: Oct 22, 2026

IBIO-610 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

IBIO-610 clinical trials

IBIO-610 · 1 trial · 1 indication

Phase 1 1
NCT07890870A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.Obesity & Overweight
NOT YET_RECRUITING32 Analytics
PHASE1NOT YET_RECRUITING
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
Obesity & Overweight
NCT0789087032
Unlock trial analytics

Study Endpoints

Primary Endpoints

Assessment of the safety and tolerability of a single dose of IBIO-610; Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.
From Day 1 through Day 252

Secondary Endpoints

Pharmacokinetics of a single dose of IBO-610
Baseline up to Week 36
Pharmacokinetics of a single dose of IBIO-610
Baseline up to Week 36
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
IBIO-610 (Cohort 1)EXPERIMENTALSingle Dose of IBIO-610; subcutaneous injection
IBIO-610 (Cohort 2)EXPERIMENTALSingle Dose of IBIO-610; subcutaneous injection
IBIO-610 (Cohort 3)EXPERIMENTALSingle Dose of IBIO-610; subcutaneous injection
IBIO-610 (Cohort 4)EXPERIMENTALSingle Dose of IBIO-600; subcutaneous injection
PlaceboPLACEBO_COMPARATORMatching Placebo; subcutaneous injection

Interventions

NameTypeDescription
IBIO-610DRUGIBIO-610; subcutaneous injection
PlaceboDRUGMatching placebo; subcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Aged 18 to 65 years (inclusive) at the time of informed consent. 2. In good general health, with no significant history and/or uncontrolled medical condition 3. BMI between ≥ 30.0 and ≤ 45.0 kg/m2 4. Able to fit in the DEXA and MRI scanners field of view in order to ensure ad...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 22, 2026NCT07890870NEW_TRIAL: changed
LOWOct 22, 2026NCT07890870NEW_TRIAL: changed

Explore more on BiopharmaWatch

iBio, Inc. (IBIO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ICompanies A to ZEvery biotech and pharma company we track